Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.49 |
| ▸ | JAK2 | O60674 | 7/20 | 0.49 |
| ▸ | JAK1 | P23458 | 5/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ADA | P00813 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22613086 | 0.94 | JAK3 (0.44) | JAK3JAK2JAK1BTKHDAC4 | |
| SCHEMBL22613084 | 0.94 | JAK3 (0.44) | JAK3JAK2JAK1BTKHDAC4 | |
| SCHEMBL22620110 | 0.94 | JAK3 (0.51) | JAK3JAK2JAK1HDAC4HDAC6 | |
| SCHEMBL22620182 | 0.93 | JAK3 (0.51) | JAK3JAK2JAK1BTKHDAC4 | |
| SCHEMBL22620108 | 0.92 | JAK3 (0.42) | JAK3JAK2JAK1HDAC4HDAC6 | |
| SCHEMBL22613444 | 0.91 | JAK3 (0.52) | JAK3JAK2JAK1 | |
| SCHEMBL22613439 | 0.91 | JAK3 (0.52) | JAK3JAK2JAK1 | |
| SCHEMBL22620140 | 0.87 | JAK3 (0.38) | JAK3JAK2JAK1HDAC4HDAC6 | |
| SCHEMBL22620184 | 0.87 | JAK3 (0.41) | JAK3JAK2JAK1HDAC4HDAC6 | |
| SCHEMBL29855244 | 0.85 | JAK3 (0.48) | JAK3JAK2JAK1BTKHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | ACLARIS THERAPEUTICS, INC. | 2022-08-23 | — | — | US | disclosed |
| US-20200347053-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020223728-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347053-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885JAK1 1/4885 |
| US-20220372034-A1 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885JAK1 1/4885 |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.